|
Organization of the Organ Systems Branch
Overview, organization, staff listing and contact information
Current SPORE Programs
Abstracts and Cores of currently funded SPOREs
Information for the Public
Information for the public interested in activities of the
SPORE program and frequently asked questions
PART Program
Information about the Patient Advocate Research Team Program
Information for Applicants
Information for researchers interested in applying for the SPORE program
IntraSPORE Communications
(access restricted to SPORE Investigators)
|
[ SPOREs:
|
|
|
|
|
|
|
|
|
|
|
|
|
]
Breast SPOREs
Breast cancer is the most common form of cancer (with the exception of non-melanoma skin cancers) diagnosed in women in the United States and is second only to lung cancer in cancer deaths. Approximately 182,800 new invasive breast cancers were identified in women in the year 2000 and about 40,800 deaths were attributed to this disease. During the course of her lifetime, a woman has a one in eight chance of developing breast cancer. Much progress has been made over the past decade in identifying hereditary factors (e.g., the BRCA1/2 predisposition genes), as well as novel therapeutic and preventative agents for breast cancer. The potential for rapidly moving laboratory discoveries into the clinic in this particular cancer site is enormous. The Breast Cancer SPORE program has grown steadily from 1992, when four sites were funded, to the present time with nine sites. The spectrum of studies supported by these grants includes the development of novel agents (e.g., liposomes,
small molecule inhibitors, anti-estrogens, retinoids, angiogenic inhibitors, vaccines, radioisotopes, antibodies), technologies (e.g., microarrays, database mining), and markers (i.e., newly identified breast cancer genes/proteins) for the better diagnosis, prognosis, screening, prevention, and treatment of breast cancer. Additional solicitations for Breast Cancer SPOREs are planned in the years 2002, 2004, and 2005.
To view the associated abstract, click on the name/address below.
|
H. Shelton Earp, III, M.D.
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
UNC School of Medicine
Campus Box 7295
Chapel Hill, North Carolina 27599-7295
Tel: 919/966-3036
Fax: 919/966-3015
|
Joe W. Gray, Ph.D.
Comprehensive Cancer Center
University of California, San Francisco
Cancer Genetics Program
2340 Sutter Street, Room N415
Box 0808
San Francisco, California 94143-0808
Tel: 415/476-3461
Fax: 415/502-2773
|
|
Kirby I. Bland, M.D.
Chairman, Dept. of Surgery
Deputy Dir., Comprehensive Cancer Ctr.
University of Alabama at Birmingham
1808 7th Ave., South
Room 502
Birmingham, AL 35233
Phone: (205) 975-2190
Fax: (205) 975-2199
|
Robert B. Dickson, Ph.D.
Lombardi Cancer Center
Georgetown University Medical Center
3970 Reservoir Road, NW
The Research Bldg., W417B
Washington, DC 20007-2197
Tel: (202) 687-3770
Fax: (202) 687-7505
|
|
C. Kent Osborne, M.D.
Breast Cancer Program
Baylor College of Medicine
Alkek N-550
Mail Station BCM 600
One Baylor Plaza
Houston, TX 77030
Phone: (713) 798-1600
Fax: (713) 798-1642
|
J. Dirk Iglehart, M.D.
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA 02115
Phone: (617) 732-6437
Fax: (617) 734-0336
|
|
V. Craig Jordan, Ph.D.
Robert H. Lurie Comp. Cancer Ctr.
Northwestern University Medical School
303 East Chicago Avenue
MS N505
Chicago, IL 60611-3008
Phone: (312) 908-4148
Fax: (312) 908-1372
|
Nancy E. Davidson, M.D.
The Johns Hopkins University
School of Medicine
The Bunting/Blaustein Building
1650 Orleans Street, 4th Floor
Baltimore, MD 21231-1000
Phone: (410) 955-8489
Fax: (410) 614-4073
|
|
Carlos Arteaga, M.D., Ph.D.
Vanderbilt University
Medical Hematology/Oncology
2100 Pierce Ave.
683 Preston Bldg.
Nashville, TN 37232
Tel: (615) 938-3524
Fax: (615) 936-1790
|
H. Kim Lyerly, M.D.
Professor, Department of Surgery, Pathology and Immunology
Duke University Medical Center
401 MSRB, Research Drive
Box 2606
Durham, NC 27710
Tel: (919) 681-8350
Fax: (919) 681-7970
|
|
